BioMarin Pharmaceutical (BMRN) versus Opiant Pharmaceuticals (OPNT) Head-To-Head Survey

BioMarin Pharmaceutical (NASDAQ: BMRN) and Opiant Pharmaceuticals (NASDAQ:OPNT) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Risk and Volatility

BioMarin Pharmaceutical has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Opiant Pharmaceuticals has a beta of -2.33, indicating that its stock price is 333% less volatile than the S&P 500.

Profitability

This table compares BioMarin Pharmaceutical and Opiant Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioMarin Pharmaceutical -12.45% -4.60% -3.09%
Opiant Pharmaceuticals 8.93% 42.44% 15.34%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for BioMarin Pharmaceutical and Opiant Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioMarin Pharmaceutical 0 5 16 1 2.82
Opiant Pharmaceuticals 0 0 0 0 N/A

BioMarin Pharmaceutical currently has a consensus price target of $114.65, indicating a potential upside of 26.74%. Given BioMarin Pharmaceutical’s higher probable upside, research analysts clearly believe BioMarin Pharmaceutical is more favorable than Opiant Pharmaceuticals.

Valuation & Earnings

This table compares BioMarin Pharmaceutical and Opiant Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioMarin Pharmaceutical $1.12 billion 14.22 -$630.21 million ($0.83) -108.99
Opiant Pharmaceuticals $18.45 million 2.80 $6.58 million $0.42 59.40

Opiant Pharmaceuticals has lower revenue, but higher earnings than BioMarin Pharmaceutical. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Opiant Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

99.0% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 1.7% of Opiant Pharmaceuticals shares are held by institutional investors. 1.9% of BioMarin Pharmaceutical shares are held by company insiders. Comparatively, 63.8% of Opiant Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit